Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955014 | 1.00 | HPGD (0.59) | HPGDLMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL14070022 | 0.84 | LMNA (0.64) | HPGDLMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL895213 | 0.79 | HPGD (0.55) | HPGDLMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL31448388 | 0.79 | HPGD (0.55) | HPGDLMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL21591953 | 0.79 | LMNA (0.46) | HPGDLMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL546296 | 0.77 | MAPT (0.56) | MAPTKMT2AL3MBTL1MEN1POLB | |
| SCHEMBL29415600 | 0.77 | MAPT (0.56) | MAPTKMT2AL3MBTL1MEN1POLB | |
| SCHEMBL4134378 | 0.75 | LMNA (0.55) | HPGDLMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL22133239 | 0.75 | LMNA (0.55) | HPGDLMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL4594814 | 0.75 | LMNA (0.59) | HPGDLMNAMAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285839-A | Preparation method of medical intermediate 6-amino piperonal | 唐美荣 | 2020-06-16 | — | — | CN | claimed |
| CN-113767090-B | Tricyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230021669-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2023-01-26 | — | — | US | disclosed |
| CN-113767090-A | Tricyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2021-12-07 | — | — | CN | disclosed |
| WO-2021143792-A1 | PIPERIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国药科大学 | 2021-07-22 | — | — | WO | disclosed |
| WO-2021136244-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2021-07-08 | — | — | WO | disclosed |
| CN-111285839-A | Preparation method of medical intermediate 6-amino piperonal | 唐美荣 | 2020-06-16 | — | — | CN | disclosed |
| CN-111285839-A | Preparation method of medical intermediate 6-amino piperonal | 唐美荣 | 2020-06-16 | — | — | CN | disclosed |
| CN-111285839-A | Preparation method of medical intermediate 6-amino piperonal | 唐美荣 | 2020-06-16 | — | — | CN | disclosed |
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| WO-2007022946-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2007-03-01 | — | — | WO | disclosed |
| US-6017918-A | Phenyl glycine compounds and methods of treating atherosclerosis and restenosis | WARNER-LAMBERT COMPANY (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0556585-A2 | Condensed camptothecin derivatives their production and use as antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-08-25 | — | — | EP | disclosed |
| EP-0138490-B1 | 4-alkyl methylenedioxy-2-1[H]-quinazolinones | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4617392-A | 4-alkyl-5,6-methylenedioxy-2-1[H]-quinazolinones useful as cardiotonic agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1986-10-14 | — | — | US | disclosed |
| EP-0138490-A1 | 4-alkyl methylenedioxy-2-1[H]-quinazolinones | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4134981-A | ANTIALLERGENS | PFIZER INC. (US) | 1979-01-16 | — | — | US | disclosed |
| US-4120962-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1978-10-17 | — | — | US | disclosed |
| US-4044134-A | FUSED WITH QUINOLINE OR PYRIDINE, 2-METHYL, ETHYL, OR ACETYL GROUP | PFIZER INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-3974161-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | HPGD 1244/4885LMNA 4251/4885MAPT 73/4885 |
| US-20230021669-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP4A11, CYP4F11, CYP11B2 | HPGD 249/4885LMNA 1304/4885MAPT 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.